Incyte Corporation (0J9P.L)
USD 69.2
(0.13%)
USD 69.2
(0.13%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 597.59 Million USD | 75.42% |
| 2022 | 340.66 Million USD | -64.09% |
| 2021 | 948.58 Million USD | 420.79% |
| 2020 | -295.69 Million USD | -166.17% |
| 2019 | 446.9 Million USD | 308.16% |
| 2018 | 109.49 Million USD | 134.97% |
| 2017 | -313.14 Million USD | -400.46% |
| 2016 | 104.22 Million USD | 1495.8% |
| 2015 | 6.53 Million USD | 113.47% |
| 2014 | -48.48 Million USD | 41.69% |
| 2013 | -83.14 Million USD | -87.61% |
| 2012 | -44.32 Million USD | 76.24% |
| 2011 | -186.54 Million USD | -485.76% |
| 2010 | -31.84 Million USD | 84.97% |
| 2009 | -211.87 Million USD | -18.42% |
| 2008 | -178.92 Million USD | -105.94% |
| 2007 | -86.88 Million USD | -17.14% |
| 2006 | -74.16 Million USD | 28.02% |
| 2005 | -103.04 Million USD | 37.48% |
| 2004 | -164.81 Million USD | 0.99% |
| 2003 | -166.46 Million USD | -21.61% |
| 2002 | -136.88 Million USD | 25.3% |
| 2001 | -183.23 Million USD | -516.23% |
| 2000 | -29.73 Million USD | -10.95% |
| 1999 | -26.8 Million USD | -865.71% |
| 1998 | 3.5 Million USD | -66.35% |
| 1997 | 10.4 Million USD | 252.94% |
| 1996 | -6.8 Million USD | 32.67% |
| 1995 | -10.1 Million USD | 12.17% |
| 1994 | -11.5 Million USD | -134.69% |
| 1993 | -4.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 106.45 Million USD | 123.94% |
| 2024 Q1 | 169.54 Million USD | -15.68% |
| 2024 Q2 | -444.6 Million USD | -362.23% |
| 2023 Q3 | 171.26 Million USD | -15.86% |
| 2023 FY | 597.59 Million USD | 75.42% |
| 2023 Q4 | 201.07 Million USD | 17.41% |
| 2023 Q1 | 21.7 Million USD | -23.74% |
| 2023 Q2 | 203.54 Million USD | 837.88% |
| 2022 Q1 | 37.99 Million USD | -93.26% |
| 2022 FY | 340.66 Million USD | -64.09% |
| 2022 Q4 | 28.46 Million USD | -74.76% |
| 2022 Q3 | 112.77 Million USD | -30.14% |
| 2022 Q2 | 161.43 Million USD | 324.91% |
| 2021 Q2 | 149.45 Million USD | 179.17% |
| 2021 Q3 | 181.73 Million USD | 21.6% |
| 2021 Q4 | 563.85 Million USD | 210.25% |
| 2021 FY | 948.58 Million USD | 420.79% |
| 2021 Q1 | 53.53 Million USD | -64.27% |
| 2020 Q3 | -15.2 Million USD | -105.24% |
| 2020 Q1 | -720.64 Million USD | -749.2% |
| 2020 Q2 | 290.29 Million USD | 140.28% |
| 2020 FY | -295.69 Million USD | -166.17% |
| 2020 Q4 | 149.85 Million USD | 1085.66% |
| 2019 Q2 | 105.31 Million USD | 2.94% |
| 2019 Q1 | 102.31 Million USD | 48.14% |
| 2019 FY | 446.9 Million USD | 308.16% |
| 2019 Q3 | 128.27 Million USD | 21.79% |
| 2019 Q4 | 111 Million USD | -13.46% |
| 2018 Q3 | 29.17 Million USD | -44.31% |
| 2018 Q4 | 69.06 Million USD | 136.71% |
| 2018 Q1 | -41.14 Million USD | 72.51% |
| 2018 FY | 109.49 Million USD | 134.97% |
| 2018 Q2 | 52.39 Million USD | 227.36% |
| 2017 Q2 | -12.48 Million USD | 93.33% |
| 2017 FY | -313.14 Million USD | -400.46% |
| 2017 Q1 | -187.08 Million USD | -2208.45% |
| 2017 Q3 | 36.05 Million USD | 388.8% |
| 2017 Q4 | -149.62 Million USD | -515.01% |
| 2016 Q3 | 36.87 Million USD | 7.12% |
| 2016 Q2 | 34.42 Million USD | 43.16% |
| 2016 FY | 104.22 Million USD | 1495.8% |
| 2016 Q1 | 24.04 Million USD | -56.42% |
| 2016 Q4 | 8.87 Million USD | -75.94% |
| 2015 Q4 | 55.17 Million USD | 239.4% |
| 2015 Q2 | 9.29 Million USD | 150.62% |
| 2015 FY | 6.53 Million USD | 113.47% |
| 2015 Q3 | -39.58 Million USD | -525.89% |
| 2015 Q1 | -18.35 Million USD | 50.31% |
| 2014 Q1 | -33.95 Million USD | 20.79% |
| 2014 Q3 | 59.29 Million USD | 260.8% |
| 2014 Q2 | -36.87 Million USD | -8.59% |
| 2014 Q4 | -36.94 Million USD | -162.31% |
| 2014 FY | -48.48 Million USD | 41.69% |
| 2013 Q4 | -42.87 Million USD | -94.54% |
| 2013 Q2 | -2.57 Million USD | 83.59% |
| 2013 Q1 | -15.66 Million USD | -183.44% |
| 2013 FY | -83.14 Million USD | -87.61% |
| 2013 Q3 | -22.03 Million USD | -757.14% |
| 2012 Q2 | 4.03 Million USD | 108.89% |
| 2012 Q4 | 18.77 Million USD | 186.5% |
| 2012 Q3 | -21.71 Million USD | -637.78% |
| 2012 Q1 | -45.42 Million USD | 17.53% |
| 2012 FY | -44.32 Million USD | 76.24% |
| 2011 Q1 | -26.51 Million USD | -181.47% |
| 2011 FY | -186.54 Million USD | -485.76% |
| 2011 Q4 | -55.07 Million USD | -3.77% |
| 2011 Q3 | -53.07 Million USD | -2.33% |
| 2011 Q2 | -51.87 Million USD | -95.65% |
| 2010 FY | -31.84 Million USD | 84.97% |
| 2010 Q4 | 32.54 Million USD | 202.65% |
| 2010 Q3 | -31.7 Million USD | -1141.43% |
| 2010 Q2 | 3.04 Million USD | 108.52% |
| 2010 Q1 | -35.72 Million USD | 59.6% |
| 2009 Q4 | -88.44 Million USD | -103.99% |
| 2009 FY | -211.87 Million USD | -18.42% |
| 2009 Q1 | -40.03 Million USD | 17.29% |
| 2009 Q2 | -40.03 Million USD | 0.0% |
| 2009 Q3 | -43.35 Million USD | -8.3% |
| 2008 Q1 | -40.15 Million USD | -84.2% |
| 2008 Q4 | -48.4 Million USD | -8.06% |
| 2008 FY | -178.92 Million USD | -105.94% |
| 2008 Q2 | -45.56 Million USD | -13.46% |
| 2008 Q3 | -44.79 Million USD | 1.69% |
| 2007 Q1 | -22.14 Million USD | -8.02% |
| 2007 Q2 | -18.43 Million USD | 16.74% |
| 2007 Q3 | -24.49 Million USD | -32.84% |
| 2007 Q4 | -21.8 Million USD | 10.99% |
| 2007 FY | -86.88 Million USD | -17.14% |
| 2006 Q2 | -20.52 Million USD | -18.57% |
| 2006 Q4 | -20.5 Million USD | -29.45% |
| 2006 Q3 | -15.83 Million USD | 22.82% |
| 2006 Q1 | -17.3 Million USD | 37.2% |
| 2006 FY | -74.16 Million USD | 28.02% |
| 2005 Q1 | -20.13 Million USD | 46.35% |
| 2005 Q4 | -27.55 Million USD | 8.79% |
| 2005 Q2 | -25.14 Million USD | -24.91% |
| 2005 Q3 | -30.21 Million USD | -20.14% |
| 2005 FY | -103.04 Million USD | 37.48% |
| 2004 FY | -164.81 Million USD | 0.99% |
| 2004 Q1 | -37.71 Million USD | 7.49% |
| 2004 Q2 | -63.6 Million USD | -68.63% |
| 2004 Q3 | -25.97 Million USD | 59.16% |
| 2004 Q4 | -37.52 Million USD | -44.46% |
| 2003 Q2 | -26.9 Million USD | 51.78% |
| 2003 Q4 | -40.76 Million USD | 5.22% |
| 2003 Q3 | -43.01 Million USD | -59.9% |
| 2003 Q1 | -55.78 Million USD | 17.35% |
| 2003 FY | -166.46 Million USD | -21.61% |
| 2002 Q4 | -67.49 Million USD | -75.71% |
| 2002 Q2 | -17.54 Million USD | -30.5% |
| 2002 FY | -136.88 Million USD | 25.3% |
| 2002 Q3 | -38.41 Million USD | -118.98% |
| 2002 Q1 | -13.44 Million USD | 90.74% |
| 2001 Q3 | -17.82 Million USD | -80.23% |
| 2001 Q2 | -9.89 Million USD | 4.08% |
| 2001 FY | -183.23 Million USD | -516.23% |
| 2001 Q4 | -145.2 Million USD | -714.52% |
| 2001 Q1 | -10.31 Million USD | -39.92% |
| 2000 Q3 | -7.59 Million USD | -15.3% |
| 2000 Q2 | -6.59 Million USD | 19.41% |
| 2000 FY | -29.73 Million USD | -10.95% |
| 2000 Q1 | -8.17 Million USD | -27.77% |
| 2000 Q4 | -7.37 Million USD | 3.0% |
| 1999 Q2 | -7.4 Million USD | -289.47% |
| 1999 Q3 | -11.1 Million USD | -50.0% |
| 1999 Q4 | -6.4 Million USD | 42.34% |
| 1999 Q1 | -1.9 Million USD | -226.67% |
| 1999 FY | -26.8 Million USD | -865.71% |
| 1998 Q4 | 1.5 Million USD | 122.06% |
| 1998 Q2 | 5.2 Million USD | 44.44% |
| 1998 FY | 3.5 Million USD | -66.35% |
| 1998 Q1 | 3.6 Million USD | -18.18% |
| 1998 Q3 | -6.8 Million USD | -230.77% |
| 1997 Q3 | 3 Million USD | 57.89% |
| 1997 FY | 10.4 Million USD | 252.94% |
| 1997 Q4 | 4.4 Million USD | 46.67% |
| 1997 Q1 | 1 Million USD | 400.0% |
| 1997 Q2 | 1.9 Million USD | 90.0% |
| 1996 Q1 | -2 Million USD | 9.09% |
| 1996 Q3 | -3.4 Million USD | -112.5% |
| 1996 FY | -6.8 Million USD | 32.67% |
| 1996 Q4 | 200 Thousand USD | 105.88% |
| 1996 Q2 | -1.6 Million USD | 20.0% |
| 1995 Q3 | -3 Million USD | -3.45% |
| 1995 Q2 | -2.9 Million USD | -45.0% |
| 1995 Q4 | -2.2 Million USD | 26.67% |
| 1995 Q1 | -2 Million USD | 47.37% |
| 1995 FY | -10.1 Million USD | 12.17% |
| 1994 Q1 | -2.1 Million USD | -50.0% |
| 1994 Q2 | -2.5 Million USD | -19.05% |
| 1994 FY | -11.5 Million USD | -134.69% |
| 1994 Q4 | -3.8 Million USD | -22.58% |
| 1994 Q3 | -3.1 Million USD | -24.0% |
| 1993 FY | -4.9 Million USD | 0.0% |
| 1993 Q3 | -1.4 Million USD | 0.0% |
| 1993 Q4 | -1.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 490.029% |
| Dynavax Technologies Corporation | -6.38 Million USD | 9453.561% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -45310.258% |
| Perrigo Company plc | -12.7 Million USD | 4805.504% |
| Illumina, Inc. | -1.16 Billion USD | 151.473% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 90.032% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 234.583% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 106.92% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 55.994% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 640.525% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 84.885% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 1599.245% |
| Waters Corporation | 642.23 Million USD | 6.95% |
| Biogen Inc. | 1.16 Billion USD | 48.532% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 331.779% |
| Evolus, Inc. | -61.68 Million USD | 1068.791% |
| Adicet Bio, Inc. | -142.65 Million USD | 518.903% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 604.248% |
| bluebird bio, Inc. | -211.91 Million USD | 382.002% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 385.594% |
| FibroGen, Inc. | -284.23 Million USD | 310.25% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 51.807% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 1439.808% |
| Homology Medicines, Inc. | -53.74 Million USD | 1211.957% |
| Geron Corporation | -184.12 Million USD | 424.558% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 235.743% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 494.236% |
| Myriad Genetics, Inc. | -112 Million USD | 633.571% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 795.732% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 224.191% |
| Zoetis Inc. | 2.34 Billion USD | 74.505% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 1202.825% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 24.237% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -256.467% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 83.49% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 1516.145% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 263.151% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 316.423% |
| Verastem, Inc. | -87.36 Million USD | 784.01% |
| Nektar Therapeutics | -276.05 Million USD | 316.477% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 349.793% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 775.398% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 211.497% |
| OPKO Health, Inc. | -188.86 Million USD | 416.419% |
| Exelixis, Inc. | 207.76 Million USD | -187.632% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -139.327% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -463.029% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 1357.971% |
| uniQure N.V. | -308.47 Million USD | 293.725% |
| Imunon, Inc. | -19.51 Million USD | 3162.258% |
| Blueprint Medicines Corporation | -506.98 Million USD | 217.873% |
| Insmed Incorporated | -749.56 Million USD | 179.726% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -112.22% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 269.73% |
| TG Therapeutics, Inc. | 12.67 Million USD | -4615.901% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 178.58% |